Comment www.thelancet.com/neurology Vol 16 July 2017 497 Corrections Doty RL. Olfactory dysfunction in neurodegenerative diseases: is there a common pathological substrate. Lancet Neurol 2017; 16: 478-88-In figure 1, the legend for panel 1B contained additional definitions. These definitions have now been removed and the legend states: "bs=basal cell undergoing mitosis. d=degenerative cell. lp=lamina propria. n=collection of axons within an ensheathing cell." Referencing errors in the Air pollution and smoking section have also been corrected. The corrected sentences now state "Air pollution might be a risk factor for mild cognitive impairment, 88 Alzheimer's disease, 89,90 and Parkinson's disease, 91 as well as possibly vascular dementia, 92 Down's syndrome, 93 schizophrenia, 94 and amyotrophic lateral sclerosis, 95 and can substantially influence smell function. 96 Although constituents of air pollution, including nanoparticles, can enter the brain via the lungs and bloodstream, the olfactory neuroepithelium is a common route. 71 These corrections have been made to the online version as of June 13, 2017.
GBCAs remain essential in the diagnosis and evaluation of disease, but require judicious use. Radiologists from the US National Institutes of Health have recommended that, in those cases for whom the use of a contrast agent is required, a macrocyclic GBCA rather than a linear agent should be considered, while also recognising when linear agents might be more beneficial-eg, in patients with documented sensitivity to macrocyclic agents. 9 Practice patterns are shifting: a study 10 published in 2017 by the Quality and Safety Committee of the Society for Paediatric Radiology reported a substantial decline in the use of linear GBCAs in children in recent years. In May, 2017, the US Food and Drug Administration released updated guidelines regarding the use of GBCAs, 11 reaffirming their previous statement that GBCAs are safe and should be used when medically necessary, but also acknowledging that results from studies show that linear GBCAs cause greater gadolinium deposition in the brain than macrocyclic GBCAs. Clinicians and researchers should be prepared to discuss the potential risk of gadolinium deposition in the brain with patients who require GBCAs. 
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